Cirrhosis Clinical Trial
Official title:
Study of Gabapentin for the Pruritus of Cholestasis
Verified date | October 2017 |
Source | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
In this study, the effect of the medication gabapentin to treat itching secondary to liver
disease is being studied.
There are some funds to cover travel expenses for patients who are not from New York (NY).
Gabapentin is approved to treat seizures in human beings. In this study, patients with liver
disease who meet inclusion criteria are admitted to the research hospital of the New York
Presbyterian Hospital to record scratching behavior by the use of a machine designed for that
purpose. Blood work will be obtained. After completion of recording, patients are assigned by
chance to receive active medication or placebo (a capsule that does not contain active
medication). The patients will come to the outpatient office of the research hospital 2 weeks
into the study for an interview and blood work. After 4 weeks, patients are readmitted to the
hospital to record scratching behavior. After data are collected, the code is broken, if
patient had been on inactive drug, active drug will be supplied as per protocol for 4 weeks.
Blood work will be obtained. If patient had been randomized to active medication, the study
will provide one week supply of drug. After that, the referring physician, with whom the
study was previously discussed, could prescribe the medication as it is available.
Status | Completed |
Enrollment | 15 |
Est. completion date | January 2004 |
Est. primary completion date | January 2004 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility |
Inclusion criteria include: - Patients from ages 18 to 80 with chronic pruritus secondary to liver disease Patients must have: - a normal chest X- ray during the previous year - normal thyroid function tests (treated thyroid dysfunction is acceptable) - controlled diabetes, if diabetes mellitus is present - negative fecal occult blood within the previous year Exclusion criteria include: - history of hepatic encephalopathy - decompensated liver disease as suggested by ascites and history of variceal bleeding - malignancy - inability to practice contraception - pregnancy - creatinine > 1.7 mg/dl - hemoglobin < 10mg/dl - S/P liver transplantation - HIV infection |
Country | Name | City | State |
---|---|---|---|
United States | Columbia University College of Physicians and Surgeons | New York | New York |
Lead Sponsor | Collaborator |
---|---|
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
United States,
Bergasa NV, McGee M, Ginsburg IH, Engler D. Gabapentin in patients with the pruritus of cholestasis: a double-blind, randomized, placebo-controlled trial. Hepatology. 2006 Nov;44(5):1317-23. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in scratching activity monitoring system | A scratching activity monitoring system specifically designed to record scratching behavior independent of gross body movement | 4 weeks | |
Secondary | Change in visual analogue scale for pruritus | 4 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01884415 -
Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis
|
Phase 3 | |
Recruiting |
NCT05014594 -
Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT
|
Phase 2 | |
Not yet recruiting |
NCT03631147 -
The Effect of Rifaximin on Portal Vein Thrombosis
|
N/A | |
Completed |
NCT04939350 -
Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
|
||
Completed |
NCT02528760 -
To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis
|
N/A | |
Recruiting |
NCT05484206 -
Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434
|
Phase 1 | |
Not yet recruiting |
NCT05538546 -
Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
|
||
Not yet recruiting |
NCT04053231 -
Hepatocarcinoma Recurrence on the Liver Study - Part2
|
||
Recruiting |
NCT02983968 -
Use of the French Healthcare Insurance Database
|
||
Completed |
NCT02705534 -
Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1
|
Phase 3 | |
Completed |
NCT02596880 -
Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics
|
Phase 3 | |
Completed |
NCT02247414 -
Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection
|
Phase 4 | |
Completed |
NCT02016196 -
Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS
|
Phase 3 | |
Withdrawn |
NCT01956864 -
Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer
|
Phase 1 | |
Completed |
NCT01362855 -
Advance Care Planning Evaluation in Hospitalized Elderly Patients
|
||
Completed |
NCT01447537 -
Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis
|
N/A | |
Completed |
NCT02113631 -
Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir
|
N/A | |
Active, not recruiting |
NCT01205074 -
¹³C-Methacetin Breath Test (MBT) Methodology Study
|
Phase 2/Phase 3 | |
Completed |
NCT01476995 -
Prognostic Indicators as Provided by the EPIC ClearView
|
N/A | |
Completed |
NCT01231828 -
Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies.
|
N/A |